Xbrane Biopharma Receives FDA Approval for Lucamzi™

Xbrane Biopharma said the FDA approved Lucamzi™, its biosimilar to Lucentis®, for retinal disorders including wet age-related macular degeneration. The company described the approval as a milestone for its commercial portfolio; the article reports no financial figures or stock-price impact.